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1684-1182/Copyright ª 2014, TaiwanObjectives: We sought to document the incidence of pediatric hospitalization for bacterial
pneumonia before universal childhood conjugate pneumococcal vaccination using two
different methods of diagnosis.
Methods: By following the World Health Organization (WHO) chest radiography (CXR) protocol,
two radiologists independently read the CXRs of a cohort of systematically recruited children
younger than 5 years. The children had acute respiratory infections and were admitted to one
of two hospitals that care for 72.5% of all pediatric admissions on Hong Kong Island. Medical
records were reviewed for clinical manifestation and to identify bacterial pneumonia diag-
nosed by pediatricians.
Results: In children younger than 5 years, the incidences of bacterial pneumonia, as diagnosed
by pediatricians and by the WHO CXR standard, were 775.7 per 100,000 population [95% con-
fidence interval (CI, 591.8e998.3)] and 439.5 per 100,000 population (95% CI, 304.6e614.5),
respectively. The study period was from 2002 to 2004.of Pediatrics and Adolescent Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong
u.hk (S.S. Chiu).
.05.007
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226 S.S. Chiu et al.Conclusion: This study provided a reliable baseline estimate of the hospitalization burden of
pneumococcal pneumonia in Hong Kong children before the advent of universal conjugate
pneumococcal vaccination.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Pneumonia causes significant morbidity in children. Strep-
tococcus pneumoniae is the leading cause of bacterial
pneumonia and accounts for an estimated 17e44% of
pneumonia admissions in young children.1,2 Routine child-
hood immunization with conjugate pneumococcal vaccines
is associated with a reduction in pneumonia hospitalization
in children.3e6 In Hong Kong, universal conjugate pneumo-
coccal vaccination in children was implemented in 2009.
We conducted a study to document the baseline pneumo-
coccal pneumonia hospitalization before the introduction
of universal vaccination with conjugate pneumococcal
vaccine and to explore the role of common respiratory vi-
ruses in children hospitalized for bacterial pneumonia.
In children, the accurate diagnosis of bacterial pneu-
monia, including pneumonia caused by S. pneumoniae, has
always been less than certain. A sputum sample is not easily
obtained from young children, and the isolation of bacteria
from sputummay only reflect colonization. Blood culture has
a very low yield because most bacterial pneumonia in chil-
dren is not bacteremic. Lung aspirate culture is more sensi-
tiveand specific, but this procedure is too invasive for routine
use in most pediatric practices because of the risk of pneu-
mothorax.7 To provide an objective endpoint in vaccine trials
that evaluate the efficacy of protection against pneumonia,
the World Health Organization (WHO) has developed a stan-
dardized protocol for diagnosing pneumonia, based on chest
radiograph (CXR) findings.8,9 The finding of alveolar consoli-
dation on CXR by two independent observers is associated
with a bacterial cause. The assumption is that S. pneumoniae
is the major etiology for bacterial pneumonia.
We compared the incidence of hospitalization for bac-
terial pneumonia as a reflection of pneumococcal pneu-
monia in Hong Kong children. We used the WHO
standardized protocol and the discharge diagnosis by pe-
diatricians to obtain the population-based age-specific in-
cidences as a baseline before the licensing and inclusion of
the conjugate pneumococcal vaccines into the universal
immunization program in Hong Kong.Materials and methods
Study design and participants
The Hong Kong Special Administrative Region (SAR) com-
prises Hong Kong Island, the Kowloon peninsula, the New
Territories, and some sparsely populated outlying islands.
In 2006, the number of people residing less than 5 years in
Hong Kong Island was 37,345 people.10 The Pamela YoudeNethersole Eastern Hospital (PYNEH) situated at the
eastern end and the Queen Mary Hospital (QMH) situated at
the south-west, are the only two public hospitals on Hong
Kong Island, with a total of 153 pediatric beds. They care
for 72.5% of all pediatric admissions on the Island. There
are 16 public hospitals with an emergency department for
all of Hong Kong SAR and noneHong Kong Island residents in
general do not cross the Harbor to Hong Kong Island for
emergency room attendance and admission for an acute
general pediatric problem. Census data were used to define
the at-risk age-stratified population.
For the purpose of this study, the CXRs of children
admitted from 2002 to 2004 were recently retrieved for
independent reading by two qualified radiologists who used
the WHO protocol. Medical records of these children were
also retrieved for review. This period was chosen because
this was the closest period before the availability of con-
jugate pneumococcal vaccine in Hong Kong. All children
younger than 5 years old who were admitted with an acute
febrile respiratory illness during one 24-hour period each
week to PYNEH (Tuesday) and QMH (Wednesday) from
September 2002 to August 2004 were specifically included.
Children with an underlying condition and a history
consistent with apparent aspiration pneumonia were
excluded. The CXRs were ordered in the emergency
department at the discretion of the emergency department
(ED) physicians or ordered after admission by the attending
pediatrician if a CXR had not been performed and the
child’s condition was considered to warrant a CXR.
Definition of pneumonia by CXR (i.e., endpoint
consolidation)
The CXRs of the patients for an admission were retrieved
and read independently by two radiologists who followed
the WHO definition and were unaware of the clinical di-
agnoses.8 Endpoint consolidation is the most specific pre-
dictor of bacterial pneumonia and is defined as a “dense
opacity that may be a fluffy consolidation of a portion or
whole of a lobe or of the entire lung, often containing air
bronchograms and sometimes associated with pleural
effusion.” The radiologists also graded the quality of the
films as “uninterpretable”, “suboptimal” or “adequate”.
The data manager monitored the disagreement between
the radiologists and those films were pulled for a consensus
reading in accordance to the WHO guidelines.
Diagnosis of bacterial pneumonia by pediatricians
For the purpose of this study, the subset of children who
were treated by the pediatrician with a full course of beta-
Pneumonia in Hong Kong children 227lactam antibiotics were assumed to have a diagnosis of
bacterial pneumonia by pediatricians. The attending pedi-
atricians made the diagnoses in routine patient care at the
time of discharge by using clinical, laboratory, and radio-
logic information. However, because the endpoint consoli-
dation categorization was conducted for this study several
years after the admissions, this information was naturally
unknown to the pediatricians.
Statistical analyses
Agreement in the diagnosis of pneumonia by different
methods of diagnosis was tested using reliability analysis. A
kappa value of less than 0.20 denotes poor agreement;
0.20e0.40, fair agreement; 0.40e0.60, moderate agree-
ment; 0.60e0.80 good agreement; and 0.80e1.00, very
good agreement.11 The Chi-square test with Yates’
correction was used to detect differences in percentages
and an unpaired t test was used to detect differences in the
counts between two groups. A significance level of p less
than 0.05 was used for all analyses. All analyses were per-
formed by SAS version 9.1 software (Cary, North Carolina,
USA).
The number of population younger than 5 years hospi-
talized for differently defined pneumonia on Hong Kong
Island was calculated by multiplying hospitalizations by 7
for the two categories of pneumonia each week (for one in
seven sampling) and then by the reciprocal of the propor-
tion of children served in the two hospitals each year (i.e.,
1O 0.725 because the two public hospitals cared for 72.5%
of all hospitalizations on Hong Kong Island). Using the age-
stratified population on Hong Kong Island, we calculated
the exact rates of hospitalization for pneumonia for each
age group. These data would be representative of the
whole Hong Kong SAR because the Hospital Authority runs
all public hospitals throughout all of Hong Kong SAR. The
size of the whole SAR is 1.04 km2 (426 square miles).
Results
A total of 441 children younger than 5 years old were
admitted at the two sites in the 2 year period with 1-in-7
days systematic sampling: 292 children were from PYNEH
and 149 children were from QMH. Three hundred and forty-
four (78%) children underwent a CXR, but 30 (8.7%) films
were missing. A review of discharge diagnoses indicated
that none of the 97 children who did not have a CXRTable 1 Comparison of the evidence of bacterial involvement
diagnosed as having bacterial pneumonia by a pediatrician or by
Bacterial pneumonia (N
Mean maximum temperature (C) 39.47  0.94
Focal crepitation, no. (%) 24 (45.3%)
Mean respiratory rate/min 38.57  11.49
Percentage with neutrophilia 33/53 (62.3%)
Antibiotic before presentation 23/53 (43.4%)
Percentage treated with a course
of beta-lactam antibiotics
53/53 (100%)performed was diagnosed as having pneumonia by pedia-
tricians. This indicated the group of children who had upper
respiratory tract infection, based on physical examination.
The median age of the 314 children who had an available
CXR was 2 years (range, 0.08e4 years). Of these children,
53 children received a discharge diagnosis of pneumonia by
the attending pediatricians. They were treated for bacte-
rial pneumonia with a full course of beta-lactam antibi-
otics. When the CXRs of these children were retrieved for
endpoint consolidation categorization, 31 children were
diagnosed as having pneumonia by the study radiologists.
Of the 64 children diagnosed by either method, 20 children
were considered to have bacterial pneumonia by pediatri-
cians and by the study radiologists using the WHO CXR
protocol, with an agreement of 86.0% (kappaZ 0.40). Eight
(25.8%) children with endpoint consolidation did not
receive treatment that was appropriate for community-
acquired bacterial pneumonia: four children never
received any antibiotics before or during hospitalization,
two children received less than 2 days of a beta-lactam
antibiotic treatment, and two children were treated with
a course of macrolide only, which would unlikely be
effective because of the extremely high incidence of
macrolide resistance in pneumococcus in Hong Kong. These
children all defervesced and were well at discharge.
There was no difference in the clinical manifestations in
children diagnosed as having bacterial pneumonia by a
pediatrician or by endpoint consolidationdwith the
exception that 100% of children diagnosed by pediatrician
were prescribed with a course of beta-lactam antibiotics,
compared to only 74.2% of children diagnosed by endpoint
consolidation (p Z 0.0005) (Table 1). Sputum culture was
performed in only five patients and was positive in two
patients. One culture grew Branhamella catarrhalis and the
other culture grew S. pneumoniae. Blood culture was per-
formed in 157 (50%) of 314 patients, and none of these
cultures grew S. pneumoniae.
Thirty CXRs were missing from our recruited patients.
We projected our finding that 31 (9.9%) of 314 available
CXRs would indicate pneumonia, based on endpoint
consolidation. We were able to have a pro rata estimation
for calculating the incidence of pneumonia defined by
endpoint consolidation. A chart review of the 30 children
with missing CXRs revealed an additional six children
diagnosed by pediatricians as having bacterial pneumonia.
Table 2 presents the projected age-specific incidences of
pneumonia hospitalization on Hong Kong Island using
various criteria. Children from 2 years to up to 5 years oldin 84 children with an available chest radiograph who were
endpoint consolidation
Z 53) Endpoint consolidation (N Z 31) p
39.49  0.98 NS
14 (45.2%) NS




Table 2 The mean annual age-specific rate of pneumonia per 100,000 children (95% confidence interval) in Hong Kong Island,
according to different criteria (2002e2004)
<2 y 2 y to <5 y Overall <5 y
Population (no.) 14,525 22,818 37,343
Discharge diagnosis of bacterial pneumonia
by pediatrician
365.6 (182.5e653.8) 1036.7 (766.9e1370.3) 775.7 (591.8e998.3)
Endpoint consolidation by radiologists 232.7 (94.1e479.6) 571.2 (376.4e831.0) 439.5 (304.6e614.5)
The data are presented as the number or as the number (confidence interval).
228 S.S. Chiu et al.had a higher incidence of pneumonia hospitalization,
compared to children younger than 2 years old who had
been diagnosed by both groups. The incidences of bacterial
pneumonia in children younger than 5 years old, as diag-
nosed by pediatricians and by the WHO CXR standard, were
775.7 per 100,000 population (95% CI, 591.8e998.3) and
439.5 (95% CI, 304.6e614.5) per 100,000 population,
respectively.
Discussion
Our overall pneumonia hospitalization incidence for chil-
dren younger than 5 years was 775.7 per 100,000 population
(by pediatrician diagnosed bacterial pneumonia) and 439.5
per 100,000 population (by endpoint consolidation) was in
general agreement with estimates based on the 2004 WHO
pneumonia disease burden data from around the world: 836
per 100,000 population for the Americas and 462 per
100,000 population for Europe; however, it was lower than
the 1775 per 100,000 population for the Western Pacific
Region.12 The incidences were not directly comparable
because our data pertained to hospitalization. It is sur-
prising that we documented a lower hospitalization inci-
dence in the less than 2 years. This was evident for both
years by the pediatricians and by the WHO criteria. A
possible explanation may be the incidence in this study only
reflected hospitalization, and not all pneumonia in-
cidences. Younger children with pneumonia in Hong Kong
may have been brought to a doctor and received treatment
sooner, thereby deterring admission. Studies from Taiwan
have also shown that suspected or definite pneumococcal
pneumonia were more likely in children 1 year up to 5 years
old, compared to other pediatric age groups.13,14 There-
fore, this may reflect a true phenomenon in Asia.
The WHO CXR protocol has been used to study
community-acquired pneumonia in hospitalized children in
Fiji, although this definition of pneumonia has been chal-
lenged as possibly underestimating the burden of pneu-
mococcal pneumonia.15e18 Bacterial pneumonia diagnosed
and treated by attending pediatricians seemed well sup-
ported by clinical and laboratory parameters and may
provide a better estimation of pneumococcal pneumonia,
compared to the WHO CXR protocol. As Madhi et al had
indicated, clinically diagnosed pneumonia is a more sensi-
tive endpoint than radiographic endpoint: in two clinical
trials evaluating the efficacy of PCV9 (Wyeth, Dallas, USA)
in South Africa and in the Gambia, the radiographic
endpoint detected only 58% of the burden of pneumonia,
based on clinical diagnosis in the first trial and 88% of
clinical pneumonia in the second trial.18e20 The population-based incidences of bacterial pneumonia hospitalization of
children in Hong Kong Island, as defined by endpoint
consolidation, was indeed 58% of the incidence as defined
by the pediatrician in charge. In this study, the specificity
of endpoint pneumonia for the diagnosis of bacterial
pneumonia is also challenged. More than 25% of children
with endpoint consolidation recovered without appropriate
treatment for pneumococcal pneumonia, which suggests a
possible overdiagnosis of pneumococcal pneumonia.
The reports of the incidence of community-acquired
pneumonia can be quite confusing when all-cause pneu-
monia is used and is compared to pneumonia, as defined by
the endpoint consolidation of the WHO CXR standard, which
is supposed to reflect a bacterial etiology. The strengths of
this study include diagnosis by pediatrician, based on clin-
ical findings and laboratory investigation at an individual
level. In addition, the set up of the public hospital system in
Hong Kong Island allowed the derivation of the age-specific
population-based pneumonia incidences.
There are limitations to this study. A small number of
CXRs could not be retrieved. Additional tests such as C-
reactive protein (CRP) or procalcitonin that may have a role
in diagnosing community-acquired pneumonia were not
used.21e23
With the availability and inclusion of conjugate pneu-
mococcal vaccines into government immunization policies,
it is important to define the pneumococcal pneumonia
hospitalization burden before and after the implementa-
tion of such policies. The seven-valent conjugate pneu-
mococcal vaccine was licensed in Hong Kong and available
to the private sector in 2005, and was incorporated into the
universal vaccination scheme in September 2009. It was
followed by the switch to the 10-valent vaccine in October
2010 and the 13-valent vaccine in December 2011. This
study provided a reliable baseline estimate of the hospi-
talization burden of pneumococcal pneumonia in Hong Kong
children before the introduction of any conjugate pneu-
mococcal vaccination into the community, which allows the
study of the impact of the conjugate vaccines after their
introduction and universal usage.
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